Predictive markers of AIDS: a follow-up of lymphocyte subsets and HIV serology in a cohort of patients with lymphadenopathy

Scand J Infect Dis. 1989;21(5):507-14. doi: 10.3109/00365548909037878.

Abstract

From 1982 to 1985, 89 HIV-1 seropositive men with persistent generalized lymphadenopathy (PGL) were enrolled into a prospective longitudinal study. In February 1988, after a mean observation time of 45 months, 23 patients had progressed to AIDS with opportunistic infection (AIDS/OI), 4 had developed Kaposi's sarcoma, 47 had developed HIV-related symptoms, 14 still had PGL as only symptom, and 1 was lost to follow-up. Patients with CD4 lymphocytes less than or equal to 0.40 x 10(9)/l as well as patients with HIV antigenaemia and those lacking antibodies to p24 all had a significantly higher risk of developing AIDS/OI within 30 months of observation than other patients. HIV antigen was present in 70% and antibodies to p24 were lacking in 61% of the patients at the time of AIDS/OI diagnosis. All but one (96%) of the AIDS/OI patients had CD4 numbers less than or equal to 0.20 x 10(9)/l at the same time. The estimated median time to AIDS/OI in patients with HIV antigenaemia was 21 months and in patients lacking p24 antibodies 27 months. In patients with CD4 numbers less than or equal to 0.20 and 0.40 x 10(9) cells/l the estimated median time to AIDS/OI was 14 months and longer than 30 months, respectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Acquired Immunodeficiency Syndrome / diagnosis*
  • Acquired Immunodeficiency Syndrome / immunology
  • Biomarkers
  • Cohort Studies
  • Gene Products, gag / immunology
  • HIV Antibodies / blood*
  • HIV Antigens / blood*
  • HIV Core Protein p24
  • HIV Seropositivity
  • HIV-1 / immunology
  • Humans
  • Leukocyte Count
  • Longitudinal Studies
  • Male
  • Opportunistic Infections / complications
  • Prognosis
  • Prospective Studies
  • Risk Factors
  • Sarcoma, Kaposi / complications
  • T-Lymphocytes*
  • Viral Core Proteins / immunology

Substances

  • Biomarkers
  • Gene Products, gag
  • HIV Antibodies
  • HIV Antigens
  • HIV Core Protein p24
  • Viral Core Proteins